Volume 7, Issue 3 (Summer 2021)                   Caspian.J.Neurol.Sci 2021, 7(3): 148-156 | Back to browse issues page

XML Print

1- Neuroscience Research Center, Department of Neurology, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
2- Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
3- Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
4- Neuroscience Research Center, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
5- Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. , andalib@health.sdu.dk
Abstract:   (376 Views)
Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke.
Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran.
Materials & Methods: In this retrospective study, 87 patients with symptoms of acute stroke were examined. They were referred to a stroke center in Gilan Province, Iran, from June 2016 to April 2020 and received r-TPA (0.9 mg/kg). Demographic information, the time interval between the onset of symptoms and r-TPA administration, complications, and National Institutes of Health Stroke Scale (NIHSS) upon arrival and discharge and death of patients were extracted from their hospital files. The paired t-test, independent t-test, and Pearson correlation test were used to compare variables using IBM SPSS for Windows version 20.0 (IBM Corp., Armonk, NY, USA).
Results: The Mean±SD of NIHSS reduced from 14.7±6.4 to 8.9±7.6 (P<0.001). The most common complication was Intracerebral Hemorrhage (ICH) (12.6%). The hospital mortality rate was 23%. ICH occurred among 40% (n=8) of those who expired, and 4.47% (n=3) of them survived, and this difference was significant (P<0.001).
Conclusion: The recovery with r-TPA administration in the stroke center was acceptable. Mortality and ICH occurrence rates were higher than other non-Iranian studies. It seems that we should change the case selection criteria and prescription dose to achieve better results of treatment with TPA.
Full-Text [PDF 1423 kb]   (199 Downloads) |   |   Full-Text (HTML)  (119 Views)  
Type of Study: Research | Subject: Special
Received: 2021/08/25 | Accepted: 2021/07/7 | Published: 2021/07/7

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.